Johnson & Johnson to buy Actelion for $30 billion
NEW BRUNSWICK, N.J. — Johnson & Johnson has reached an agreement to acquire Switzerland-based biopharmaceutical company Actelion Ltd. for $30 billion in cash. J&J said Actelion’s differentiated, innovative products for pulmonary arterial hypertension (PAH) are highly complementary to the portfolio of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company also noted that the
